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1. Introduction
1.1. The challenge to induce lasting remission in late stage melanoma
In early stages of the disease surgical resection of melanoma lesions is a curative option; a 10-
year-survival rate of 75-85% can be achieved in stage I or II of the disease. However, stage III
or IV melanoma is associated with low survival rates of less than 1 year upon diagnosis [1].
The poor prognosis in advanced stages of the disease is thought to be particularly due to the
properties of melanoma cells to systemically spread into various organs, to form micro-
metastases beyond the detection limit of current imaging procedures [2, 3] and to give rise to
relapse of the disease. This is even the case after initially complete response to therapy and
after more than a decade from initial treatment. Durable remission is so far only achieved in
pre-defined patient subsets despite the development of novel drugs and major improvements
in therapeutic regimens [4-6]. This unsatisfactory situation is thought to be due to the extra‐
ordinary property of melanoma cells to persist in “dormancy” for long periods of time which
is associated with their resistance to chemo-and radiotherapy [7-10]. Taken together, durable
cure from melanoma requires eliminating single melanoma cells in a highly specific and
efficient fashion even in dormant micro-metastatic lesions.
In this situation recruiting the cellular immune defense machinery to detect and destroy
individual melanoma cells is a powerful alternative to conventional therapeutic regimens. The
hope is sustained by the supportive effect of high dose interleukin-2 (IL-2) [11] and anti-
cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody [12] as well as interferon
(IFN) α-2b to prolong the disease-free survival even in late stages of the disease. However, the
response rate is quite low and frequently not curative over time [13, 14].
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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A number of strategies for sharpening the immune cell response against melanoma are
currently explored, some of these with remarkable success. In particular, the adoptive transfer
of tumor infiltrating lymphocytes (TILs), isolated from melanoma biopsies and amplified to
therapeutic relevant numbers ex vivo, produced encouraging phase II results [15, 16]. In a
further development, patients’ blood T cells are genetically engineered with pre-defined
specificity for melanoma-associated antigens making adoptive cell therapy with melanoma
specific T cells possible. In this contribution we will discuss the rationale for adoptive cell
therapy of melanoma, evidence for efficacy and current challenges to achieve long-term
remission. Upcoming strategies in melanoma stem cell targeting are also discussed.
2. Adoptive therapy with ex vivo amplified TILs can induce regression of
melanoma
An effective immune response can control melanoma. This notion is supported by the
observation that spontaneous and complete melanoma regressions can occur and that immune
compromised patients suffer from a higher frequency of melanoma [17, 18]. The conclusion is
moreover sustained by the clinical observation that treatment with high dose IL-2 produces
an objective response even in late stage melanoma, some patients with long-term complete
response for years [11, 19]. Although about 16%, the response rate is remarkable compared to
the low and short-lived response rates of classical therapeutic regimens.
First described in 1969 [20], melanoma is infiltrated by T cells of both effector and helper cell
origin which can be expanded to high numbers ex vivo in the presence of IL-2. Pioneered by
the NCI-Surgery Branch, such tumor infiltrating T cells (TILs) were selected for melanoma
reactivity by incubation on feeder cells expressing melanoma-associated antigens [21] and re-
administered in substantial numbers together with high dose IL-2 to the patient (Figure 1).
Initial trials produced an objective response rate of 11/20 patients [22] which is remarkable
since TILs are obviously capable to fight melanoma even in late stage patients who experienced
multiple lines of therapy. Responses, however, were of short duration and TILs did not persist
for longer period in the peripheral blood after administration. Subsequent trials identified that
the key to successful TIL therapy was the number of TILs administered to the patient, the
activity of those cells against melanoma and the rapidity of T cell amplification ex vivo [23,
24]. During the subsequent years the initial protocols were optimized with respect to these and
other issues and adopted according to GMP standards [25]; a number of trials are currently
open in various centers (Table 1).
Persistence of administered TILs in circulation was substantially improved by depletion of the
lymphoid compartment of the patient prior to adoptive cell therapy [26-28]. Such pre-
conditioning by non-myeloablative chemotherapy had the effect that cytokines sustaining
lymphocyte amplification including IL-7 and IL-15 were present in augmented levels ("cyto‐
kine sink"). Moreover, space for transferred lymphocytes was created and suppressor cells
including regulatory T cells were depleted which additionally helped to improve engraftment
of adoptively transferred T cells.
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Target
antigen
Adoptively transferred T cells and additional treatment NCT ID Center
TILs, IL-2 in variable doses NCT00001832 NIH
TILs vs. lymphokine-activated killer (LAK) cells NCT00002535 StLMC
TILs, high dose IL-2 NCT00096382 NIH
TILs, low dose IL-2 s.c. NCT00200577 NUH
TILs with vs. without IL-2 NCT00314106 NIH
TILs, high dose IL-2 with or without dendritic cell immunization NCT00338377 MDACC
TILs, high dose IL-2 NCT00604136 HMC
TILs, high dose IL-2 NCT00863330 AHC
TILs, high dose IL-2 NCT00937625 HUH
TILs, high dose IL-2 NCT01005745 MOFFITT
TILs, low dose IL-2 and intra-tumoral injection of IFN-γ
producing adenovirus
NCT01082887 NUH
TILs, high dose IL-2 NCT01659151 MOFFITT
TILs, high dose IL-2 NCT01701674 MOFFITT
TILs, high dose IL-2 NCT01807182 FHCRC
"re-stimulated"(autologous DCs &anti-CD3 antibody) TILs, low
dose IL-2
NCT01883297 UHN
TILs, low dose IL-2 NCT01883323 UHN
TILs, dendritic cell vaccination with NY-ESO-1 NCT01946373 KUH
TILs, high vs. low dose IL-2 NCT01995344 CHNHSFT
4-1BB selected TILs NCT02111863 NIH
“young“ TILs, high dose IL-2 NCT00287131 SMC
“young“ TILs with or without CD4+ T cell depletion, high dose
IL-2
NCT00513604 NIH
“young“ CD8+ TILs, high dose IL-2 NCT01118091 NIH
“young“ TILs, high dose IL-2 NCT01319565 NIH
“young“ TILs, high dose IL-2 NCT01369875 NIH
“young“ TILs, IL-15 NCT01369888 NIH
“young“ TILs NCT01468818 NIH
“young“ TILs, high dose IL-2, BRAF kinase inhibitor NCT01585415 NIH
“young“ TILs, with or without high dose IL-2 NCT01814046 NIH
“young“ TILs, anti-CTLA-4 antibody NCT01988077 SMC
“young“ TILs, high dose IL-2 with standard vs. low dose
chemotherapy
NCT01993719 NIH
Aurora Health Care; CHNHSFT, Christie Hospital NHS Foundation Trust; FHCRC, Fred Hutchinson Cancer Research
Center; HMC, Hadassah Medical Center; HUH, Herlev University Hospital (Copenhagen); KUH, Karolinska Universi‐
ty Hospital; MDACC, M.D. Anderson Cancer Center; MOFFITT, H. Lee Moffitt Cancer Center and Research Institute;
MUH, Mie University Hospital; NIH, National Institutes of Health; NUH, Nantes University Hospital; SMC, Sheba
Medical Center; StLMC, St. Luke's Medical Center; UC, University of California; UHN, University Health Network
(Toronto)
Table 1. Adoptive cell therapy with tumor infiltrating lymphocytes (TILs) in patients with melanoma
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There are still some issues to be addressed, for instance whether clinically most potent TILs
can be defined by phenotype and whether these cells can be selectively expanded. There
is a common sense that for therapeutic efficacy in the long-term the functional activity of
T cells needs to be preserved without signs of exhaustion which is particularly crucial when
T  cells  experienced  extensive  amplification  ex  vivo.  In  the  further  development  of  the
procedure, TILs were only selected with respect to their proliferative capacities which is
independent of their antigen specificity and represents a furthermore simplification of the
standard protocol (Figure 1) [29-31]. Those so-called “young TILs” after short-term ex vivo
expansions passed through fewer cell division cycles prior to infusion and are thereby in
a  maturation  stage  less  prone  to  terminal  differentiation  and  senescence  [32].  Those
protocols do not further select TILs for their melanoma reactivity based on the observa‐
tion that infusion of ex vivo activated, IFN-γ+TILs produced no superior therapeutic efficacy
compared  to  non-responding  TILs  [16].  These  modifications  in  the  protocol  resulted  in
improved persistence of young TILs [33] and about 50% response rates [27, 29, 34], so far
in  non-randomized trials  (Table  1).  A series  of  recent  clinical  trials  with TILs following
different  lympho-conditioning regimes  resulted  in  objective  responses  in  56% and com‐
plete responses in 22% of patients at the Surgery Branch [35]. Current TIL trials at various
centers reproduced objective response rates of 40-50% in melanoma patients, a significant
portion of patients free of disease 3-5 years after treatment [36, 37]. Of note, TILs can have
anti-tumor activity also towards brain metastases as shown in a NCI trial with 7/17 complete
and 6/17  partial  remissions  [38]  sustaining  the  hope  that  adoptive  cell  therapy  may be
effective towards metastases which are otherwise not accessible.
While most trials apply non-separated TILs, administration of isolated CD8+T cell clones with
specificity for Melan-A and gp100 mediated only moderate benefit, required IL-2 and did not
persist for longer times [39]. Those CD8+T cells which persisted long-term acquired a pheno‐
type of central memory-type T cells in vivo [40]. It is therefore assumed that CD8+TILs require
help of CD4+cells for prolonged persistence making application of non-separated T cell
populations more suitable.
Not only the stage of maturation but also the recruitment of T cells through chemokine
gradients is crucial for therapeutic success. A recent prospective-retrospective hypothesis-
driven analysis revealed that coordinate over-expression of CXCL9, CXCL10, CXCL11, CCL5
in melanoma is associated with responsiveness to treatment after TIL therapy [41].
Melanoma-reactive T cells need to persist in circulation to ensure therapeutic success of TIL
therapy [42, 43]. This is reflected by the median survival of patients treated with Melan-A
specific TILs of 53.5 months compared to 3.5 months for patients who received TILs of
unknown specificity [44]. Some trials are initiated using melanoma specific patient's T cells
from the peripheral blood for adoptive cell therapy of melanoma (Table 2). MART-1 or gp100
specific T cell clones isolated and amplified ex vivo produced a 50% response rate [45],
however, technical difficulties limit a broad application of such specific T cells since melanoma
reactive T cells in the peripheral blood of melanoma patients are extremely rare.
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Target antigen Adoptively transferred T cells NCT ID Center
MAGE-1 or
MAGE-3
melanoma specific CD8+ T cells NCT00045149 FHCRC
Tyrosinase tyrosinase specific CD8+ T cells NCT00002786 FHCRC
MART-1 MART-1 specific CD8+ T cells with or without high dose IL-2 NCT01495572 NIH
MART-1 MART-1 specific CD8+ T cells NCT00512889 DFCI
MART-1 MART-1 specific T cells NCT00720031 NUH
MART-1 MART-1 specific CD8+ T cells NCT00324623 CHUV
MART-1 MART-1 specific TILs, high dose IL-2 NCT00924001 NIH
MART-1 MART-1 specific CD8+ T cells, low dose IL-2 NCT01106235 FHCRC
NY-ESO-1 NY-ESO-1 specific CD8+ T cells, low dose IL-2, anti-CTLA-4
antibody
NCT00871481 FHCRC
CHUV, Centre Hospitalier Universitaire Vaudois; DFCI, Dana-Farber Cancer Institute; FHCRC, Fred Hutchinson Can‐
cer Research Center; NIH, National Institutes of Health; NUH, Nantes University Hospital
Table 2. Adoptive cell therapy with autologous, antigen specific T cells in patients with melanoma
Figure 1. T cells used in adoptive cell therapy of melanoma. (A) Tumor infiltrating T cells (TILs) are isolated from
melanoma biopsies, selected for reactivity towards melanoma cells, amplified in the presence of IL-2 to clinically rele‐
vant numbers and infused to the patient. Alternatively, TILs are expanded without prior selection for melanoma reac‐
tivity using a short-term amplification protocol ("young TILs"). (B) T cells from the peripheral blood of melanoma
patients are genetically modified by retro- or lentivirus transduction to express a recombinant T cell receptor (TCR) or
a chimeric antigen receptor (CAR), specific for a melanoma associated antigen, amplified and administered to the pa‐
tient.
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3. T cells with engineered anti-melanoma specificity
The success of melanoma antigen specific T cells from peripheral blood strengthened efforts
to obtain melanoma-specific T cell clones by genetic engineering of patient's T cells from the
peripheral blood. In particular, the molecular cloning of the TCR from melanoma-reactive T
cells enabled the engraftment of melanoma specificity to any T cell (Figure 1) [46-49]. A TCR
with specificity for gp100 was cloned from melanoma reactive TILs and transferred by
retrovirus-mediated gene transfer into blood T cells which thus obtained redirected specificity
for gp100+cells in addition to their parental specificity. TCR engineered T cells recognized
gp100+melanoma cells, secreted pro-inflammatory cytokines including IFN-γ and lysed
gp100+melanoma cells [50, 51]. By the same strategy, blood T cells were modified with the TCR
specific for other melanoma associated antigens (Table 3). Using T cells modified with a gp100
specific TCR objective response was induced in 19% of patients, most responses were persistent
[49]. Melanoma regression was also obtained in 5/11 melanoma patients after transfer of T cells
modified with a TCR that recognizes NY-ESO-1, a protein encoded by a member of the cancer/
germline family of genes [52, 53].
Melanoma regression was obtained in about 30% of patients after cell therapy with MART-1
specific T cells [49, 52, 54-56]. As a side effect, patients suffered from vitiligo and destruction
of melanocytes in the eye and ear indicating that T cells with engineered specificity can target
rare and healthy cells even with the cognate antigen at low levels. In a recent trial, patients
were treated with T cells engineered with an anti-MAGE-A3 TCR [57]. While 5/9 patients
experienced melanoma regression, three of them had mental status changes and two lapsed
into coma and died. Histology revealed necrotizing leukoencephalopathy which is likely due
to the recognition of previously unknown epitopes of MAGE-A9/A12, the latter expressed in
the brain.
Prolonged clinical remission was observed when engineered T cells persisted in the circulation
for longer times; TCR modified T cells were recorded in the blood for more than a year after
initiation of treatment [56, 58]. Moreover, TCR engineered T cells were capable to penetrate
the blood-brain barrier and to induce regression of brain metastases [57] giving hope that
patients with metastases at otherwise incurable sites may benefit from adoptive cell therapy.
However, tumor cells may become invisible to TCR modified T cells due to repression of the
MHC complex [60], β2 microglobulin mutation [61], and deficiencies in the antigen processing
machinery [60, 62], all of them resulting in diminished antigen presentation and less TCR-
mediated T cell activation.
Engineering T cells with a recombinant TCR may produce a safety hazard when the transgenic
αβ TCR forms hetero-dimers with the respective α and β TCR chains of the endogenous TCR.
Such mis-pairing of TCR chains can induce severe auto-reactivity as a result in gain of an
unpredictable specificity [63, 64]. The situation was technically solved by different means
including replacing the human by the homologous murine constant moieties of the TCR [65]
and by inserting additional cysteine bridges [66] to facilitate preferential pairing of the
recombinant TCR αβ chains in the presence of the physiologic αβ TCR. These and other
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technical difficulties of the TCR strategy promoted the development of an artificial “all-in-one"
receptor molecule to redirect T cells in an antigen-restricted fashion as summarized below.
Target antigen Adoptively transferred T cells NCT ID Center
IL-12 engineered TILs NCT01236573 NIH
IL-2 engineered TILs NCT00062036 NIH
CXCR2 and NGFR transduced TILs, high dose IL-2 NCT01740557 MDACC
TGF-Beta resistant (DNRII) and NGFR transduced TILs, high dose IL-2 NCT01955460 MDACC
gp-100 anti-gp-100 TCR engineered CD8+ cells, anti-gp-100 TCR engineered TILs, high
dose IL-2
NCT00085462 NIH
gp-100 anti-gp-100 TCR engineered T cells, high dose IL-2 plus gp-100 vaccination NCT00610311 NIH
gp-100 & MART-1 anti-gp-100 TCR & anti-MART-1 TCR engineered T cells high dose IL-2 Peptide
Immunization
NCT00923195 NIH
MAGE-A3 anti-MAGE-A3/12 TCR engineered T cells, high dose IL-2 NCT01273181 NIH
MAGE-A3 anti-MAGE-A3 TCR engineered T cells, high dose IL-2 NCT02153905 NIH
MAGE-A3 anti-MAGE-A3-DP4 TCR engineered CD4+ cells, high dose IL-2 NCT02111850 NIH
MAGE-A4 anti-MAGE-A4 TCR engineered T cells NCT02096614 MUH
MAGE-A4 anti-MAGE-A4 TCR engineered T cells NCT01694472 TMUCIH
MART-1 anti-MART-1 TCR engineered T cells, IL-2, peptide immunization NCT00091104 NIH
MART-1 anti-MART-1 TCR engineered T cells, IL-2, MART-1 peptide pulsed dendritic cells NCT00910650 UC
MART-1 anti-MART-1 TCR engineered T cells, high dose IL-2, peptide immunization NCT00612222 NIH
MART-1 anti-MART-1 TCR T cells vs. anti-MART-1 TCR TILs, high dose IL-2 NCT00509288 NIH
MART-1 anti-MART-1 TCR engineered T cells, low dose IL-2, peptide immunization NCT00706992 NIH
NY-ESO-1 anti-NY-ESO-1 TCR engineered T cells, high dose IL-2 NCT00670748 NIH
NY-ESO-1 anti-NY ESO-1 mTCR engineered T cells, high dose IL-2 NCT01967823 NIH
NY-ESO-1 anti-NY ESO-1 TCR CD62L+ T cells, high dose IL-2 NCT02062359 NIH
NY-ESO-1 anti-NY-ESO-1 TCR engineered T cells NCT01350401 Adaptimmune
NY-ESO-1 anti-NY-ESO-1 TCR engineered T cells, cotransduced with IL-12 cDNA NCT01457131 NIH
p53 anti-p53 TCR engineered T cells, high dose IL-2, p53 peptide pulsed dendritic cells NCT00704938 NIH
p53 anti-p53 TCR engineered T cells, high dose IL-2 NCT00393029 NIH
tyrosinase anti-tyrosinase(368-376) TCR engineered T cells NCT01586403 LU
GD2 3rd generation anti-GD2 CAR engineered T cells NCT02107963 NIH
VEGFR2 anti-VEGFR2 CAR engineered CD8+ T cells, low dose IL-2 NCT01218867 NIH
LU, Loyola University (Chicago); MDACC, M.D. Anderson Cancer Center; MUH, Mie University Hospital; NIH, National Institutes of
Health; TMUCIH, Tianjin Medical University Cancer Institute and Hospital; UC, University of California;
Table 3. Adoptive cell therapy with engineered antigen specific T cells in patients with melanoma
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4. CAR T cells with engineered specificity for melanoma
In order to link antigen recognition with the downstream signaling machinery of the TCR,
Zelig Eshhar (Weizmann Institute of Science) reported a chimeric antigen receptor (CAR)
molecule, also named immunoreceptor, which is composed in the extracellular moiety of a
single chain fragment of variable region (scFv) antibody for binding and in the intracellular
moiety of the CD3ζ endodomain to initiate T cell activation [67]. The coding sequence of such
recombinant receptor molecule is transferred by retro- or lentiviral transduction into T cells in
vitro (Figure 1) [68]. CAR engineered T cells, also nick-named “T-bodies”, recognize their new
target by CAR binding and become activated to secrete pro-inflammatory cytokines, to amplify
and to lyse the cognate target cells. Since the binding domain is derived from an antibody the
CAR recognizes the target in a MHC-independent fashion which makes major differences to
TCR mediated T cell recognition. For instance, the CAR recognizes its target independently of
the individual HLA subtype and CAR T cells are not affected by MHC repression and loss of
HLA molecules on target cells which frequently occurs during tumor progression. However,
recognition by CARs is restricted to target antigens on the cell surface; intracellular antigens
like transcription factors are not visible to CAR T cells. Despite that limitation, a nearly infinite
variety of targets can be recognized including those which are not classical T cell targets like
carbohydrates and gangliosides [69].
Full and lasting T cell activation requires two complementary signals, one provided by the
TCR/CD3 and the other by co-receptors the prototype of which is CD28. Prolonged T cell
activation, however, requires costimulation and autocrine factors, in particular IL-2 which is
only secreted upon TCR and simultaneous CD28 signaling. The lack of appropriate costimu‐
lation in the tumor lesion provides the rationale for combining the intracellular CD3ζ with the
CD28 signaling domain in one polypeptide chain of a "second generation" CAR (Figure 2). A
CAR with combined CD28-CD3ζ signaling domain provides both the primary CD3ζ and the
required costimlatory signal when engaging the cognate target. CARs with a costimulatory
domain clearly provide clinical benefit and improved T cell persistence compared to CARs
with the CD3ζ domain only [70-72]. Other costimulatory moieties, such as 4-1BB (CD137) and
OX40 (CD134), also provide full T cell activation when linked to CD3ζ in a CAR; the individual
costimulory domains have different impact on T cell effector functions [73]. These and other
costimulatory domains were furthermore combined in so-called "3rd generation" CARs which
provide advantage for matured effector T cells in terminal differentiation but less in younger
stages of T cell development [74]. A number of additional modifications of the CAR design
were explored in order to improve T cell persistence and activation and finally the anti-tumor
response [75, 76].
While the antibody domain defines the target specificity of the CAR, a plethora of antigens
can potentially be used as target for the adoptive cell therapy of melanoma. T cells engineered
for targeting melanoma-associated antigens include CARs with specificity for HMW-MAA,
also known as MCSP [77, 78], melanotransferrin [79], and the gangliosides GD2 [80] and GD3
[81]. Trials are currently recruiting; to our best knowledge no published data are so far
available.
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During the last years spectacular efficacy was achieved with CAR T cells in phase I trials for
the treatment of lymphoma/leukemia [82, 83]. Clinical response and prolonged T cell activation
was accompanied by a "cytokine storm", which occurred even weeks after initial T cell
administration; the side effect can clinically be managed by treatment with a neutralizing anti-
IL-6 antibody without affecting the anti-tumor efficacy.
The enthusiasm in CAR T cell therapy, however, was dampened by reports on serious adverse
events and fatalities after CAR T cell administration [84, 85]. Targeting ErbB2 produced
respiratory failure which is thought to be due to low levels of antigen on a number of healthy
cells which are sufficient to trigger "on-target-off-organ" T cell activation [86]. This and other
serious adverse events emphasize a careful evaluation of potential targets and the necessity
for T cell dose escalation studies to balance anti-tumor efficacy and auto-immunity [75, 87, 88].
Figure 2. T cells with engineered specificity. T cells physiologically recognize their target by the T cell receptor (TCR)
complex which is composed of the TCR α and β chain for recognition and the CD3 chains for signaling. The variable
regions of each TCR chain (Vα and Vβ) together bind to the MHC presented antigen, Cα and Cβ represent the constant
domains. T cells can be genetically engineered with defined specificity by expression of recombinant TCR αβ chains of
known specificity. In contrast to the TCR, the chimeric antigen receptor (CAR) is one polypeptide chain composed of a
single chain fragment of variable region (scFv) antibody for antigen recognition, the extracellular spacer domain, a
trans-membrane domain and the intracellular CD3ζ ("first generation" CAR), the CD28-CD3ζ ("second generation"
CAR), or the CD28-OX40-CD3ζ ("third generation" CAR) signaling chain.
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5. "Melanoma stem cells": Target cells to achieve long-term remission?
Despite the tremendous cellular and phenotypic heterogeneity in tumor lesions, cancer is
thought to be initiated and maintained by so-called cancer stem cells (CSCs). Such pluripotent
stem cells are of low abundance, induce tumors upon transplantation under limiting dilution
conditions, resist radiation and chemotherapy, and drive self-renewal and a-symmetric
differentiation into a variety of cell types. Residual CSCs are thought to initiate cancer relapse
even after years of “dormancy”, which can be more than a decade after surgical treatment of
the primary lesion [89]. While the concept of the hierarchical organization in driving tumor
progression was initially drawn upon deciphering hematological malignancies, basically the
same organization was subsequently reported for other solid cancers including mammary,
prostate, pancreatic, colon carcinoma and glioma [90-94].
Transplantation of melanoma cell subsets into recipient mice under limiting dilution condi‐
tions also revealed that a defined subset of cancer cells, and not every cell from the same biopsy,
can induce tumors of same histology as the parental tumor [90, 95-97]. One conclusion is that
melanoma is organized in a hierarchical manner originating from a particular initiator cell, the
cancer stem cell, which gives rise to the described diversity of cells in an established lesion.
Melanoma initiating cells were described by various, but not common markers, including the
transporter protein ABCB5 [95], CD20 [97], or the nerve growth factor receptor CD271 [98].
While CD271+melanoma cells are present in a frequency of approximately 1/2000 cells [98],
transplantation under more rigorous conditions, i.e., ideally of one single melanoma cell,
revealed that nearly every fourth randomly taken melanoma cell (1/2-1/15) can induce tumors
in the host animal. This observation, however, questioned the validity of the stem cell para‐
digm for melanoma [99, 100]. Subsequent studies made clear that the potential to induce
melanoma is not closely associated with a particular phenotype and that the number of
potential CSCs in melanoma may not necessarily be low. If nearly every melanoma cell is
capable to re-program to a tumor initiating cell under certain conditions, blocking stem cell
properties in melanoma will reduce tumor initiation and growth in a transplantation model
finally resulting in melanoma ablation [101].
Once the tumor lesion is established, a minor subset of cancer cells seems to take over to control
malignant progression. Evidence for this hypothesis was provided from a pre-clinical model
[79] which asked whether all or a defined subset of melanoma cells in an established xeno-
transplanted lesion need to be eliminated to cause tumor regression. Such melanoma sustain‐
ing cell may be, but not must be identical to melanoma stem cells identified by transplantation
assays.
Evidence for a particular targetable melanoma cell subset which sustains tumor progression
was provided by the observation that elimination of CD20+melanoma cells by adoptive transfer
of CAR T cells completely eradicated xeno-transplanted melanoma. Those human melanoma
biopsies contained a subset of CD20+melanoma cells which constituted about 1-2% of mela‐
noma cells and which are present in different histological melanoma types and tumor stages.
A caveat is that in approximately 20% of melanoma samples analyzed so far, no
CD20+melanoma cells were detected by histological screening; CD20-specific CAR T cells did
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not induce regression of those transplanted tumor lesions. Interestingly, CD20 re-expression
in a random subpopulation of those tumor cells by genetic modification did not render the
tumor lesion sensitive for eradication indicating that CD20 expression per se is not sufficient
but requires additional capabilities to sustain melanoma progression [79].
There are additionally clinical observations that sustain the notion of CD20+cells in promoting
melanoma progression. Firstly, a patient with stage III/IV metastatic, refractory melanoma and
2% CD20+melanoma cells who received intra-lesional injections of the anti-CD20 therapeutic
antibody rituximab experienced lasting remission accompanied by a decline of the melanoma
serum marker S-100 to physiological levels and a switch of a T helper-2 to a more pro-
inflammatory T helper-1 response [102]. Although anecdotic, data provide the first clinical
evidence that targeted elimination of CD20+melanoma cells can produce regression of
chemotherapy-refractory melanoma. Secondly, in a small pilot trial, stage IV melanoma
patients without evidence of disease by way of surgery, chemo-and/or radiation therapy
received the anti-CD20 antibody systemically for a 2 year period [103]. Data suggest a benefit
of anti-CD20 therapy in overall and recurrence-free survival; a caveat being that the number
of patients is still small for definitive conclusions.
Currently, the hierarchical stem cell model in the maintenance of an established melanoma is
supported by some experimental evidence [79], whereas a body of information on melanoma
initiation by transplantation of single melanoma cells sustains the stochastic model [99, 100],
although not confirmed by others [98]. The most determining proof of the stem cell hypothesis,
however, will be the successful melanoma elimination by targeting stem cells or stem cell
properties. For the development of such therapeutic strategies several aspects need to be taken
into account.
First, standard therapy will rapidly de-bulk the tumor lesion and the remaining melanoma
stem cells, which are more chemo-and radiation resistant, will drive relapse of the disease.
Since those melanoma initiating cells are merely in a "dormant" state and replicate less
frequently than the majority of melanoma cells in the same lesion, anti-proliferative strategies
by classical chemotherapeutic drugs are unlikely efficient. Transporter systems including
ABCB5, which is highly expressed by melanoma stem cells [95], additionally contribute to
chemotherapy resistance; the chemotherapy and/or radiation itself may promote expression
of those transporter systems and survival of those resistant cells which finally contributes to
relapse of the disease.
Second, if clinical progression correlates with the prevalence of CD20+melanoma cells, targeted
elimination of those melanoma cells requires to meet the fact that those target cells are a small
minority. Targeted elimination, e.g., by CD20 redirected cytotoxic T cells or by CD20-specific
therapeutic antibodies like Rituxan™ (rituximab) or Arzerra™ (ofatumumab), will be required
to obtain substantial efficacy.
Third, the extraordinary functional and phenotypic plasticity of melanoma cells may make it
necessary to have the therapeutic agent in place for a longer time. In their pre-clinical model,
Schmidt and colleagues [79] used CAR T cells which persist for long-term acting as an antigen-
specific guardian as long as target cells are present. Since repetitive re-stimulation sustains the
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persistence and amplification of CAR T cells, cellular therapy has a major advantage compared
to pharmaceutical drugs with a comparable short half-life. CAR T cells can moreover provide
antigen-specific memory with defined specificity [104], potentially contributing to control
melanoma in the long-term.
6. Production of engineered T cells for clinical application
Application of adoptive cell therapy to clinical use requires efficient production of cells
according to good manufacturing practice (GMP). This particularly applies to patient’s T cells
which are ex vivo genetically modified. The vector used for T cell modification is of major
relevance with respect to the efficiency and stability in modification. Crucial steps in this
process are the stable integration of the genetic vector, the site of integration to avoid insertion
mutagenesis, and the resistance of the vector to genetic repression. To date, most clinical trials
were performed employing retroviral or lentiviral vectors which fulfill some but not all of these
requirements. Recently, other vector systems including RNA modification are alternatively
utilized and it is expected that these systems will be explored in parallel in the near future.
The way of stimulating the T cells ex vivo for genetic modification and subsequent amplifica‐
tion is crucial for both the success in transduction and the functional capacities of modified
cells. T cells are commonly activated by TCR/CD3 stimulation in addition to IL-2 [105]; most
protocols use anti-CD3 and anti-CD28 magnetic beads [83, 106] which can be easily eliminated
during the production process. IL-2 is replaced by other cytokines such as IL-7 and IL-15 to
obtain a T cell population with a more naive and central memory phenotype [107]. Alterna‐
tively, cell lines were engineered, so-called “artificial APCs”, which are modified with the
various co-stimulating molecules to mimic the physiological stimulation and to provide the
required signals [108]. However, difficulties in adopting those cells to GMP standard prevent
their broad application in large scale production processes.
For the production itself, static culture systems in flasks or gas permeable bags are traditionally
used. Due to their amplification at low cell densities (0.25-1x106 cells per ml), high culture
volumes are required to obtain clinically relevant T cell numbers which is more easily achieved
by non-static systems including the WAVE-Bioreactor or the G-Rex100 device [83, 106, 109].
In order to produce engineered T cells for a large number of patients it will be required to
manufacture cells in a closed system and to produce multiple batches in parallel in the same
clean room facility without the risk of batch contamination.
7. Challenges and promise in the adoptive cell therapy of melanoma
To date, approximately half of the melanoma patients benefit from adoptive cell therapy with
TILs. Specifically targeted T cells may further improve the therapeutic response. Despite
substantial success, the strategy still has major challenges which need to be addressed in the
near future.
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Significant numbers of effector T cells have to accumulate in the targeted tumor lesion which
is mediated by a network of chemokines. Adoptively transferred T cells use these networks to
accumulate at the tumor site; melanoma cells secrete a number of chemokines including
CXCL1 to attract lymphocytes. However, early imaging studies revealed that melanoma-
specific T cells massively infiltrate the lungs, spleen and liver with only some accumulation at
the tumor site before the cells decline to undetectable levels in circulation [110-112]. To improve
tumor targeting TILs were engineered with CXCR2, the receptor for melanoma secreted
CXCL1, which resulted in improved anti-tumor activity in a mouse model [113]. The strategy
is currently being explored in an early phase I trial (Table 3) [113].
Since tumor eradication requires a beneficial T cell-to-target cell ratio, higher numbers of
tumor-specific T cells applied per dose likely increase the clinical efficacy. The optimal dose
of T cells, however, is still a matter of discussion and requires empiric evaluation. A number
of trials, in particular applying TILs, administered up to 1010 cells per dose [27]. Such high
doses in turn require extended expansions of T cells ex vivo with the risk of loss of the "young"
phenotype and gain of more matured T cells. Highly expanded T cells become hypo-responsive
to CD28 costimulation and rapidly enter activation induced cell death, in particular upon IL-2
driven expansion [114]. With respect to more potent effector functions short-term amplification
protocols are envisioned for both TILs and engineered T cells. This may be achieved by T cell
amplification in the presence of IL-15 and IL-21 and/or by 4-1BB co-stimulation [115].
On the other hand, administration of about 105 engineered T cells induced remarkable
therapeutic efficacy in recent trials targeting CD19+ leukemia [83]. Since the T cells substantially
amplify in vivo upon antigen encounter, the capacity of cells to amplify under appropriate
conditions is more relevant than the applied cell number.
Once targeted in sufficient numbers to the tumor tissue, a major challenge is the tumor
selectivity of redirected T cells. While the TCR and the CAR is specific for a particular target,
in most cases the targeted antigen is not exclusively expressed by cancer but also by healthy
cells, although sometimes at lower levels [116, 117]. MART-1, frequently expressed by the
majority of melanoma cells, is also expressed by melanocytes. Targeting such type of antigen
frequently produces vitiligo, sometimes also inner ear toxicity with a certain degree of deafness
[49]. Since nearly all "tumor-associated antigens" which are frequently used as targets for
adoptive cell therapy are self-antigens, strategies are needed to minimize such off-target
toxicities. Among these, low-avidity TCRs or CARs or combinatorial antigen recognition by
two CARs are currently explored.
Melanoma  cells  may  become  invisible  to  TILs  or  TCR  modified  T  cells  due  to  down-
regulation of their MHC components or due to deficiencies in antigen processing. Howev‐
er, melanoma cells may still be visible to CAR T cells which recognized their target by their
antibody-derived binding domain in a MHC independent fashion. On the other hand, TCR
T  cells  are  capable  to  recognize  cross-presented  antigen,  for  instance  tumor  antigen
presented by stroma cells, which is invisible to CAR T cells but helps to destroy the tumor
lesion in the long-term [118, 119].
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Consequently, a TCR-like CAR aims at combining the benefits of TCR and CAR redirected T
cells. This is performed by using a single chain antibody with TCR-like specificity for recog‐
nizing MHC presented antigen. T cells with such a TCR-like CAR were successfully redirected
in a MHC restricted fashion towards NY-ESO-1 and MAGE-A1, respectively [120, 121].
The redirected T cell activation depends on the amount of target antigen and binding affinity.
Compared to TILs and TCR modified T cells, CAR T cells bind with extraordinary high affinity
by their antibody-derived CAR binding domain. A furthermore increase in affinity by affinity
maturation does not necessarily improve CAR redirected T cell activation [120, 122]; CD28
costimulation does not add to the affinity dependent activation threshold, however, prolongs
T cell persistence and resistance to apoptosis [123]. Targeting cancer cells also depends on the
amount of target antigen in addition to the binding affinity. Low affinity CARs require
abundant antigen levels for efficient activation of engineered T cells while high affinity CARs
are likewise effective against low antigen levels on target cells. In this context, the selectivity
in targeting melanoma cells versus healthy cells needs to be discussed not only with respect
to the targeted antigen itself but also to antigen amount and binding affinity.
Amplification and persistence of adoptively transferred cells correlates with clinical outcome
in some trials [124]. T cells will persist in detectable numbers as long as targeted antigen is
present, however, will contract to undetectable levels and disappear from circulation when no
target is furthermore present. To enable survival of CAR T cells in the long-term, Epstein-Barr
virus (EBV)-specific T cells were used as effector cells and modified with a tumor-specific CAR.
The rationale is that EBV specific T cells are maintained in a sizable population in circulation
by recognizing EBV antigens by their physiological TCR. The strategy is sustained by the first
clinical observation that EBV-specific T cells engineered with an anti-GD2 CAR showed benefit
over non-virus-specific, CAR engineered T cells in the treatment of neuroblastoma
(NCT00085930) [124]. Other trials use EBV or CMV specific, autologous T cells engineered with
a first or second generation CAR, for instance directed against HER2/neu (ErbB2)
(NCT01109095), CD30 (NCT01192464), or CD19 (NCT00709033; NCT01475058; NCT01430390;
NCT00840853; NCT01195480).
The T cell subset matters, adoptively transferred CD8+T cell clones poorly persist [125] and
need help of CD4+cells. Prolonged T cell anti-tumor response also requires resistance to
repression in the tumor tissue. A number of efforts are currently undertaken to counteract
tumor associated T cell repression, in particular mediated by Treg cells and checkpoint
mediators. In animal models, CD28 costimulation without induction of IL-2 secretion protects
a CAR redirected T cell response from Treg cell repression [126]. On the other hand, repetitive
T cell stimulation upregulates CTLA-4 which acts as negative regulator to return the T cell to
a resting stage. Administration of a CTLA-4 blocker, e.g., ipilimumab antibody, may prolong
the anti-tumor activation of transferred T cells, although it is not locally restricted and will
likewise affect all T cells [127, 128]. Expression profiling of TCR-engineered T cells demon‐
strates overexpression of multiple inhibitory receptors in persisting lymphocytes, including
PD-1 and CD160, the latter associated with decreased reactivity of TCR T cells in a ligand
independent manner [129]. Essentially the same was observed for CAR T cells [130]. These
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analyses point to a multi-factorial T cell repression in the tumor tissue; there is more than one
uni-directional strategy needed to sustain the T cell anti-tumor response in the long-term.
A major hurdle of specific immunotherapy in general is the tremendous heterogeneity of
cancer cells within the same lesion. Low or loss of target antigen expression negatively affects
the long-term therapeutic efficacy of an antigen-redirected approach. This is supported by
several reports which document a relapse of antigen-loss tumor metastases after adoptive
therapy with melanoma-reactive T cell clones [39,131, 132]. A solution may be the use of
polyclonal T cells with specificities for various melanoma antigens or T cells modified with
different CARs recognizing different antigens; however, target-negative tumor cells will not
be recognized. On the other hand, pro-inflammatory cytokines secreted by redirected T cells
upon activation can attract a second wave of innate immune cells which in turn may eradiate
the antigen-negative tumor cells. At least in an animal model, antigen-negative melanoma cells
are indeed eliminated when co-inoculated with antibody-targeted cytokines [133]. T cells
engineered with induced expression of transgenic IL-12 can attract innate immune cells
including macrophages into the tumor tissue which eliminate antigen-negative tumor cells in
the same lesion, at least in an immune competent animal model [134]. Such "TRUCK" cells ("T
cells redirected for unrestricted cytokine killing") may pave a novel way to deliver transgenic
cell products to pre-defined, target lesions.
Combination of adoptive cell therapy with pathway inhibitors may improve the efficacy in
melanoma cell elimination, in particular in disseminated stages of the disease. Metastatic
melanoma patients with the B-raf activating mutation V600E benefit from a small molecule
drug, PLX4032 or vemurafenib, which inhibits the mitogen-activated protein kinase (MAPK)
pathway. Treatment with vemurafenib is accompanied by increased T cell infiltrations in the
melanoma lesions [135, 136] which may contribute to the therapeutic effect and may be
improved by co-administration of melanoma-specific T cells.
While adoptive cell therapy is mostly performed with modified or non-modified T cells, other
cells like monocytes, macrophages as well as NK cells can also be redirected by CARs in an
antigen-specific fashion [137-141, 144]. In contrast to T cells, NK cells can be rapidly activated
and exhibit high cytotoxic potential and continuously growing NK cell lines such as NK-92
can be used for adoptive cancer immunotherapy [142]. CD3ζ chain CARs trigger cytolytic
activities of NK cells which has been shown for CARs with various specificities [138, 141,
143-147]. Similar to T cells, the anti-tumor activity was improved by adding 4-1BB or 2B4
(CD244) costimulatory domains [148, 149]. Since NK cells cannot provide IL-2 or IL-15 required
for amplification, CAR modified NK cells were additionally engineered to release IL-15 which
sustains NK cell expansion and CAR-mediated cytotoxicity in the absence of IL-2 [150]. Despite
these and other advances during the last years, experience with CAR engineered primary NK
cells in clinical trials is still limited; whether redirected cells of the innate immune system are
more advantageous in melanoma elimination than modified T cells has moreover to be
explored in clinical trials.
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